Selskabets formål er at forske i, udvikle, producere og markedsføre farmaceutiske, medicinske og tekniske produkter og ydelser samt anden dertil knyttet virksomhed efter bestyrelsens nærmere bestemmelse. Selskabet tilstræber at drive sin virksomhed på økonomisk, miljømæssigt og socialt ansvarlig vis.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 309.1 mia. | 102.4 mia. | 542.9 mia. | 194 mia. | 76343 | |
CVR: 24256790
Secondary names: NOVO TERAPEUTISK LABORATORIUM A/S, NOVO INDUSTRI A/S, NORDISK GENTOFTE A/S
Previous names: NOVO INDUSTRI A/S, NOVO-NORDISK A/S
73 properties
Upgrade to Pro to see addresses, building data and ownership details
Companies in the same industry and area
CVR 32083560
CVR 45480941
CVR 36423641
CVR 39842319
CVR 41598263
Hassan Kassem joined the board
Désireé Jantzen Asgreen joined the board
Tanja Villumsen joined the board
Tamara Schmidt joined the board
Helena Ildiko Saxon joined the board
Ramona Audry Sequeira joined the board
Johannes Gerardus Joseph van de Winkel joined the board
Semsi Kilic Madsen joined the board
Trine Hartvig Kristiansen joined the board
Liselotte Sofie Hyveled-Nielsen left the board
Compared to 131 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Novo Nordisk A/S exhibits strong financial health, characterized by robust profitability and significant revenue generation. In 2025, the company reported a revenue of 229.92 billion DKK and a profit of 75.54 billion DKK, indicating a solid profit margin. The revenue trend shows growth from 204.72 billion DKK in 2024 to 290.40 billion DKK, reflecting a strong upward trajectory. With equity standing at 169.90 billion DKK in 2025, the company maintains a healthy equity position, although the slight decline from previous years may warrant attention. As a major player in the pharmaceutical manufacturing industry, Novo Nordisk is well-positioned for continued success.
AI-generated summary
companydata.dk